Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: Analyze real-world usage and impact of a predictive low-glucose suspend (PLGS) insulin delivery system for maintenance of euglycemia and prevention of hypoglycemic events in people with insulin-dependent diabetes. Methods: Retrospective analysis of Tandem Basal-IQ users who uploaded at least 21 days of PLGS usage data between August 31, 2018, and March 14, 2019 ( N = 8132). Insulin delivery and sensor-glucose concentrations were analyzed. The times spent below 70 mg/dL, between 70 and 180 mg/dL, and above 180 mg/dL were assessed. Subgroup analyses were conducted to examine matched pre-/postoutcomes with experienced users ( n = 1371) and performance over time for a mixed subgroup with >9 weeks of data ( n = 3563). Results: The mean age of patients was 32.4 years, 52% were female, 96% had type 1 diabetes, and 4% had type 2 diabetes. Mean duration on PLGS was 65 days. Algorithm introduction led to a 45% median relative risk reduction in sensor time <70 mg/dL, pre/post (% <70:2.0, 1.1), while the mean glucose remained stable (168 and 168 mg/dL). Mean frequency of hypoglycemic events decreased from one every 9 days to one every 30 days. Total daily insulin dose decreased from 43.4 to 42.3 U in the pre/post subgroup. Manual override of the system was low (4.5%). The number of daily suspensions remained stable (4.9). Conclusions: Introduction of PLGS resulted in effective and sustained prevention of hypoglycemia without a significant increase in mean blood glucose and may be considered for people with type 1 diabetes at risk for hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Wild, D., von Maltzahn, R., Brohan, E., Christensen, T., Clauson, P., & Gonder-Frederick, L. (2007) · Patient Education and Counseling · doi:10.1016/j.pec.2007.05.003 · Cited by 545
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., & Kollman, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0362 · Cited by 42
Cited by
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Pinsker, J. E., Müller, L., Constantin, A., Leas, S., Manning, M., McElwee Malloy, M., Singh, H., & Habif, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0388 · Cited by 147
“7,8 We believe that the positive user experience of the t:slim X2 insulin pump with Basal-IQ technology facilitated these individuals with diabetes to achieve these results, 3 results that were actually better than those seen in the pivotal PROLOG trial.”
Self-citationArtificial Intelligence and Machine Learning Applied at the Point of Care
Angehrn, Z., Haldna, L., Zandvliet, A. S., Gil Berglund, E., Zeeuw, J., Amzal, B., Cheung, S. Y. A., Polasek, T. M., Pfister, M., Kerbusch, T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00759 · Cited by 93
“Secondly, data published on real-world use of Basal-IQ technology has demonstrated even greater reductions in time spent below 3.9 mmol/L (70 mg/dl) than those seen in the pivotal trial (Muller et al., 2019).”
InfluentialWeight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions
Zaharieva, D. P., Addala, A., Simmons, K. M., & Maahs, D. M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00411-z · Cited by 21
Metadata
- Authors
- Müller, L., Habif, S., Leas, S., & Aronoff-Spencer, E.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2019-09-01
- Volume
- 21
- Issue
- 9
- Pages
- 478-484
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2963316214
- Cited by
- 24
- References
- 7
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort. https://app.cochat.ai/papers/10.1089/dia.2019.0190
- The paper
- Müller, L., Habif, S., Leas, S., & Aronoff-Spencer, E. (2019). Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2019.0190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.